Skip to content

Himferra Capsules for Anemia

A Clinical Comparative study to evaluate the safety and efficacy of Himfera capsules in the Management of Iron Deficiency Anaemia - HC

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/12/010959
Enrollment
40
Registered
2017-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- individuals with Iron Deficiency Anaemia (IDA)

Interventions

Intervention1: Himfera Capsules: Each Himfera capsule contains: Pdrs. Shuddha Kasisa (Ferrous sulphate) 150 mg Exts. Shunti (Zingiber officinale) 17 mg Amalaki (Emblica officinalis) 38 mg Pun

Sponsors

The Himalaya Drug Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of both sexes in the age group of 18-70 years with Hemoglobin Subjects who have clinical symptoms such as pale skin colour, extreme fatigue, irritability, weakness, brittle nails, palpitation, headache, loss of appetite. Subjective improvement in quality of life in subjects with Iron deficiency anaemic. Subjects willing to give written informed consent. Subjects who have not participated in similar kind of study in last 3 months.

Exclusion criteria

Exclusion criteria: Subjects with hemoglobin concentration Blood hemoglobin level Absence of iron binding protein, hereditory spherocytosis and any association of severe complication. Pregnant & lactating women. Not willing to sign informed consent form.

Design outcomes

Primary

MeasureTime frame
Change in anaemia-related blood parameter levels An improvement in biochemical parameters viz. serum iron hemoglobin levels and erythrocyte counts. Improvement in symptoms such as skin pallor, tiredness and lack of energy, headache, weakness, low performance, appetite, breathlessness and feeling of wellbeing. Subjective improvement in quality of life in subjects with Iron deficiency anaemic. Timepoint: Patients will be followed up and the results were assessed from baseline on visit days: Visit 0- Baseline Visit 1 - At the end of Month 1 Visit 2- At the end of Month 2 (End of the study)

Secondary

MeasureTime frame
Compliance of the subject to the drug treatment and the adverse effects will be noted.Timepoint: Patients will be followed up and the results were assessed from baseline on visit days: Visit 0- Baseline Visit 1 - At the end of Month 1 Visit 2- At the end of Month 2 (End of the study)

Countries

India

Contacts

Public ContactDr R Mohandhas

Ramya Hospital

dr.palani@himalayawellness.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026